Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$106.44 USD

106.44
1,088,790

-1.65 (-1.53%)

Updated Jul 30, 2024 04:00 PM ET

After-Market: $106.33 -0.11 (-0.10%) 7:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Thermo Fisher (TMO) Rides on APAC Strength Despite Cost Woes

Thermo Fisher (TMO) is registering a sturdy global footprint with strong growth seen in Asia-Pacific including China.

Medtronic Moves a Step Ahead With Mazor Robotics Buyout

Medtronic's (MDT) resolve to take over the Israel-based robotic surgical guidance systems company, Mazor Robotics, adheres to its goal to grow in the sphere of robotics spine surgery.

Hill-Rom Rides on New Products, Asia Pacific Sales Drop

Hill Rom (HRC) sets sights on product innovation. In patient support systems, the company unveils Hill-Rom Envella Air Fluidized Therapy Bed.

GNC Holdings Domestic Revenues Soft, Global Growth Strong

Within same store, GNC Holdings (GNC) disappoints on the domestic franchise locations front. However, its steadily thriving international business is a big boon.

Will Strong RTG Arm Shape Medtronic's (MDT) Q2 Earnings?

Medtronic (MDT) poised to gain on continued RTG business growth in Q2.

Here's Why You Should Invest in Illumina (ILMN) Stock Now

llumina (ILMN) set to take over peer in a $1.2-billion deal, which will strengthen its position in the genomics market.

Baxter (BAX) Launches Peri-Strips & Tisseel Prima, Shares Up

Baxter's (BAX) diversified surgical portfolio lends it a competitive edge in the MedTech space.

Here's Why You Should Hold Becton, Dickinson (BDX) Stock Now

Solid fiscal Q4 for Becton, Dickinson (BDX); headwinds apprehended in fiscal 2019.

ResMed (RMD) Closes MatrixCare Buyout, Boosts SaaS Line

Post culmination of the transaction, MatrixCare will continue to operate as a standalone business within ResMed's (RMD) SaaS portfolio.

Haemonetics Strong on Plasma & Hemostasis Management Units

Haemonetics (HAE) sees encouraging growth at the North America Plasma revenues on strong disposables along with growing software revenues.

NuVasive Porous PEEK Implant OK'd for Use in XLIF Procedure

NuVasive (NUVA) adopts initiatives to boost the U.S. Spinal Hardware unit.

Here's Why You Should Buy Integer Holdings (ITGR) Stock Now

Integer Holdings' (ITGR) bullish guidance paints a bright picture. Moreover, its solid focus on portfolio management is likely to provide the company with a competitive edge in the MedTech space.

Bio-Rad Clinches USDA Contract, Boosts Life Science Segment

Bio-Rad (BIO) adopts initiatives to boost Life Science unit.

BD's FDA Nod for Phoenix Test Boosts Diagnostic Systems

BD's (BDX) diagnostics portfolio boasts tests used for rapid susceptibility testing.

ResMed's Out-of-Hospital Line to Grow With MatrixCare Buyout

MatrixCare consolidation is expected to enhance ResMed's (RMD) capacity to improve patient transitions of care as well as its provider skills.

Masimo (MASI) Beats on Q3 Earnings, 2018 Guidance Impressive

Masimo (MASI) gains from strong Product revenues in Q3; raises 2018 outlook.

Masimo (MASI) Beats Q3 Earnings and Revenue Estimates

Masimo (MASI) delivered earnings and revenue surprises of 4.41% and 2.06%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Medical Product Stock Q3 Earnings on Oct 31: BAX, MASI & More

Long-term growth prospects of the Medical Products industry looks promising despite certain short-term political conundrums.

Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, Margins Down

We are encouraged by Zimmer Biomet's (ZBH) consistent effort in product renovation through research and development.

Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q3

Omnicell's (OMCL) third-quarter 2018 performance impresses with year-over-year growth in earnings and revenues.

ResMed (RMD) Q1 Earnings & Sales Beat on Overall Growth

ResMed (RMD) sees solid contributions from domestic and international businesses in Q1.

Will Advance Medical Buyout Aid Teladoc (TDOC) Q3 Earnings?

Teladoc (TDOC) is expected to chip in with a solid top-line contribution from its acquisition of Advance Medical in Q3.

Can CAG Growth Steadily Drive IDEXX (IDXX) in Q3 Earnings?

IDEXX's (IDXX) efforts to enhance its commercial capabilities in the United States to maintain a recurring revenue rise at CAG Diagnostics are encouraging.

Will Product Revenues Drive Masimo's (MASI) Q3 Earnings?

Masimo's (MASI) Product revenues likely to drive Q3; guidance for 2018 raised.

Align Technology (ALGN) Beats on Earnings and Revenues in Q3

Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q3.